Equities

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc

Actions
  • Price (USD)1.39
  • Today's Change-0.08 / -5.46%
  • Shares traded14.23k
  • 1 Year change+2.97%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Medexus Pharmaceuticals Inc share price to rise to 3.00 in the next year from the last price of 1.39.
High116.6%3.00
Med116.6%3.00
Low116.6%3.00

Earnings history & estimates in USD

On Nov 07, 2024, Medexus Pharmaceuticals Inc reported 2nd quarter 2025 breakeven earnings per share. This result was in line with the consensus of the 3 analysts following the company and outperformed last year's 2nd quarter results by 0.05.
The next earnings announcement is expected on Feb 10, 2025.
Average growth rate+42.22%
Medexus Pharmaceuticals Inc reported annual 2024 losses of -0.01 per share on Jun 25, 2024.
More ▼

Revenue history & estimates in USD

-32768 had 2nd quarter 2025 revenues of 26.30m. This bettered the 26.01m consensus of the 4 analysts covering the company. This was 16.64% below the prior year's 2nd quarter results.
Average growth rate-3.10%
-32768 had revenues for the full year 2024 of 113.05m. This was 4.59% above the prior year's results.
Average growth rate+22.76%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.